JP2008535899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535899A5 JP2008535899A5 JP2008505955A JP2008505955A JP2008535899A5 JP 2008535899 A5 JP2008535899 A5 JP 2008535899A5 JP 2008505955 A JP2008505955 A JP 2008505955A JP 2008505955 A JP2008505955 A JP 2008505955A JP 2008535899 A5 JP2008535899 A5 JP 2008535899A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound according
- compound
- pharmaceutically acceptable
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 62
- 150000003839 salts Chemical class 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 12
- 239000002671 adjuvant Substances 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 238000006243 chemical reaction Methods 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- -1 n- butoxymethyl Chemical group 0.000 claims 5
- 101150116411 AGTR2 gene Proteins 0.000 claims 4
- 201000006549 dyspepsia Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000005859 coupling reaction Methods 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000008484 agonism Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 230000001969 hypertrophic effect Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 1
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 101150059573 AGTR1 gene Proteins 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 206010002659 Anovulatory cycle Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000017283 Bile Duct disease Diseases 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000002881 Colic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000007542 Paresis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 230000007654 ischemic lesion Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000016087 ovulation Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 206010038464 renal hypertension Diseases 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 230000035922 thirst Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67025705P | 2005-04-12 | 2005-04-12 | |
| US60/670,257 | 2005-04-12 | ||
| PCT/GB2006/001332 WO2006109056A1 (en) | 2005-04-12 | 2006-04-12 | New tricyclic angiotensin ii agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012253303A Division JP5625029B2 (ja) | 2005-04-12 | 2012-11-19 | 新規な三環系アンジオテンシンｉｉアゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008535899A JP2008535899A (ja) | 2008-09-04 |
| JP2008535899A5 true JP2008535899A5 (enExample) | 2009-05-14 |
| JP5289043B2 JP5289043B2 (ja) | 2013-09-11 |
Family
ID=36616971
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505955A Expired - Fee Related JP5289043B2 (ja) | 2005-04-12 | 2006-04-12 | 新規な三環系アンジオテンシンｉｉアゴニスト |
| JP2012253303A Expired - Fee Related JP5625029B2 (ja) | 2005-04-12 | 2012-11-19 | 新規な三環系アンジオテンシンｉｉアゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012253303A Expired - Fee Related JP5625029B2 (ja) | 2005-04-12 | 2012-11-19 | 新規な三環系アンジオテンシンｉｉアゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8067418B2 (enExample) |
| EP (1) | EP1869024B1 (enExample) |
| JP (2) | JP5289043B2 (enExample) |
| KR (1) | KR101284573B1 (enExample) |
| CN (2) | CN104109156A (enExample) |
| AT (1) | ATE487713T1 (enExample) |
| AU (1) | AU2006235706B2 (enExample) |
| CA (1) | CA2604038C (enExample) |
| DE (1) | DE602006018122D1 (enExample) |
| ES (1) | ES2384450T3 (enExample) |
| MX (1) | MX2007012635A (enExample) |
| WO (1) | WO2006109056A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006109056A1 (en) * | 2005-04-12 | 2006-10-19 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| ES2442003T3 (es) * | 2007-06-20 | 2014-02-07 | Mitsubishi Tanabe Pharma Corporation | Nuevo derivado de sulfonamida de ácido malónico y uso farmacéutico del mismo |
| JP5451611B2 (ja) | 2007-07-26 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター |
| AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| CA2708303A1 (en) | 2007-12-11 | 2009-06-18 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| TW200934490A (en) | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| WO2009094169A1 (en) | 2008-01-24 | 2009-07-30 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CA2714532A1 (en) | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| US8598160B2 (en) | 2008-02-15 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| TW201004945A (en) | 2008-05-01 | 2010-02-01 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| KR20110002492A (ko) | 2008-05-01 | 2011-01-07 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CA2723032A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8846668B2 (en) | 2008-07-25 | 2014-09-30 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2010011314A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
| CN102224151A (zh) | 2008-11-20 | 2011-10-19 | 万能药生物有限公司 | 新的抗微生物剂 |
| JP5679997B2 (ja) | 2009-02-04 | 2015-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤 |
| UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
| WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
| RU2012102094A (ru) | 2009-06-26 | 2013-08-10 | Панацеа Биотек Лтд. | Новые азабициклогексаны |
| WO2011002910A1 (en) | 2009-07-01 | 2011-01-06 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| WO2011161128A1 (en) | 2010-06-25 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
| CA2813671A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| MX376108B (es) | 2012-12-20 | 2025-03-07 | Tempest Therapeutics Inc | Compuestos de triazolona y usos de los mismos. |
| AU2014315151A1 (en) | 2013-09-06 | 2016-03-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| WO2015152393A1 (ja) | 2014-04-03 | 2015-10-08 | 国立研究開発法人国立循環器病研究センター | 悪性腫瘍転移抑制用医薬 |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
| EP3820498A1 (en) | 2018-06-14 | 2021-05-19 | University College Cork-National University of Ireland Cork | Peptide for disease treatment |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
| IE64514B1 (en) | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
| DE4023215A1 (de) | 1990-07-21 | 1992-01-23 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung |
| IE920175A1 (en) | 1991-02-11 | 1992-08-12 | Zeneca Ltd | Nitrogen heterocycles |
| US5252574A (en) * | 1991-04-26 | 1993-10-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted thiophene or furan |
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| CZ36394A3 (en) | 1991-08-19 | 1994-07-13 | Du Pont | Substituted imidazilonone derivatives and pharmaceutical preparations based thereon |
| CZ36294A3 (en) | 1991-08-19 | 1994-07-13 | Du Pont | Substituted imidazilonone derivatives and pharmaceutical preparations based thereon |
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| GB9223371D0 (en) | 1992-11-06 | 1992-12-23 | Ici Plc | Heterocyclic compounds |
| US5395844A (en) | 1993-06-10 | 1995-03-07 | The Du Pont Merck Pharmaceutical Company | Imidazole 5-position substituted angiotensin II antagonists |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| WO1998005624A1 (en) * | 1996-08-06 | 1998-02-12 | Taisho Pharmaceutical Co., Ltd. | Amino compounds and angiotensin iv receptor agonists |
| EP0855392A3 (de) * | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| DE10112041A1 (de) * | 2001-03-14 | 2002-09-26 | Aventis Pharma Gmbh | p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE60222409T2 (de) | 2001-05-31 | 2008-09-25 | Vicore Pharma Ab | Trizyklische verbindungen, nützlich als angiotensin ii agonisten |
| WO2003064414A1 (en) | 2002-01-29 | 2003-08-07 | Vicore Pharma Ab. | Tricyclic compounds useful as angiotensin ii agonists |
| JP4385113B2 (ja) * | 2002-09-18 | 2009-12-16 | 株式会社ポーラファルマ | 新規ビフェニルイミダゾピリジン誘導体及びそれを有効成分とする医薬 |
| WO2004046128A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New bicyclic angiotensin ii agonists |
| AU2003302027A1 (en) * | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| AU2003302106A1 (en) * | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| JP3874419B2 (ja) * | 2003-01-31 | 2007-01-31 | 三共株式会社 | 動脈硬化及び高血圧症の予防及び治療のための医薬 |
| WO2004085420A1 (en) | 2003-03-24 | 2004-10-07 | Vicore Pharma Ab | Bicyclic compounds useful as angiotensin ii agonists |
| WO2006109056A1 (en) * | 2005-04-12 | 2006-10-19 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
-
2006
- 2006-04-12 WO PCT/GB2006/001332 patent/WO2006109056A1/en not_active Ceased
- 2006-04-12 CN CN201410212290.6A patent/CN104109156A/zh active Pending
- 2006-04-12 AU AU2006235706A patent/AU2006235706B2/en not_active Ceased
- 2006-04-12 KR KR1020077025441A patent/KR101284573B1/ko not_active Expired - Fee Related
- 2006-04-12 CN CNA2006800209222A patent/CN101193887A/zh active Pending
- 2006-04-12 CA CA2604038A patent/CA2604038C/en not_active Expired - Fee Related
- 2006-04-12 US US11/918,238 patent/US8067418B2/en not_active Expired - Fee Related
- 2006-04-12 AT AT06726732T patent/ATE487713T1/de not_active IP Right Cessation
- 2006-04-12 DE DE602006018122T patent/DE602006018122D1/de not_active Expired - Lifetime
- 2006-04-12 EP EP06726732A patent/EP1869024B1/en not_active Expired - Lifetime
- 2006-04-12 ES ES06726732T patent/ES2384450T3/es not_active Expired - Lifetime
- 2006-04-12 MX MX2007012635A patent/MX2007012635A/es active IP Right Grant
- 2006-04-12 JP JP2008505955A patent/JP5289043B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-19 JP JP2012253303A patent/JP5625029B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5625029B2 (ja) | 新規な三環系アンジオテンシンｉｉアゴニスト | |
| JP2008535898A5 (enExample) | ||
| KR101629181B1 (ko) | 피롤 화합물 | |
| KR101280198B1 (ko) | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 | |
| JP2015178457A (ja) | ピラゾロピリジン誘導体、またはその薬理学的に許容される塩 | |
| KR101280160B1 (ko) | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 | |
| WO2012102297A1 (ja) | ピラゾロピリジン誘導体、またはその薬理学的に許容される塩 | |
| JP5718301B2 (ja) | 新規な三環系アンジオテンシンｉｉアゴニスト | |
| CN106795099B (zh) | 用于治疗高血压和心血管疾病的前药和组合物 | |
| AU653281B2 (en) | Imidazopyridines | |
| CA2832996C (en) | Tricyclic triazole compounds and their use as aldosterone synthase inhibitors | |
| EA003697B1 (ru) | Дизамещенные бициклические гетероциклы, их получение и применение в качестве лекарственных средств | |
| TW200800185A (en) | Acid secretion inhibitor | |
| CA2825172A1 (en) | Indole derivative and pharmacologically acceptable salt of same | |
| JP2015178458A (ja) | ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩 | |
| CZ114593A3 (en) | Imidazopyridine derivatives, process of their preparation and pharmaceutical preparations in which they are comprised | |
| CN109153672A (zh) | Trpv4拮抗剂 | |
| US5500427A (en) | Cyclic compounds and their use | |
| HUT62576A (en) | Process for producing substituted imidazolylpropenoic acid derivatives and pharmaceutical compositions comprising such compounds | |
| JP2004533457A5 (enExample) | ||
| JP2000309534A (ja) | 血管新生阻害剤 | |
| JP2008535900A5 (enExample) | ||
| CN105612150B (zh) | 磺酰吲哚衍生物和制备该磺酰吲哚衍生物的方法 | |
| CN101098867B (zh) | 取代的亚砜类化合物和其制备方法及用途 | |
| JPWO2002022595A1 (ja) | Ｎ置換ベンゾチオフェンスルホンアミド誘導体 |